"You did it. You crazy son of a b*tch, you did it." - the graveyard of failed IL-33 drugs, probably
Who would’ve thought the “everybody thought it would fail” reads a metric f*ck ton better when the thing doesn’t… well, fail. AstraZeneca rolled into the big lung conference in Barcelona this week with full late-stage data on tozorakimab (gesundheit), its experimental COPD biologic, and the drug Wall Street was modeling at approximately zero dollars just swept both Phase 3 trials.
The numbers, if you’re wondering, were feral. The once-a-month shot cut moderate and severe flare-ups by 29% and 34% in former smokers, and 30% and 29% in the broader population of current and former smokers, all on top of standard inhalers. Bigly. The FDA already has it under priority review, with US approval expected in the first quarter of 2027.
Now, in case you don't follow respiratory pipelines for fun, IL-33 (read: the protein that makes your lungs angrier than woke women Patrick Clancy haters) is the target where biologic programs go to die. Friendly reminder that Sanofi and Regeneron ran their own IL-33 drug, itepekimab, through two Phase 3s in May and went 1-for-2. The miss cut flare-ups by as little as 2%, which, basically placebo. Regeneron got nuked 18% in a day, and the whole industry got body bagged moved on from the target.
CEO Pascal Soriot put it best saying, "Everybody thought it would fail." He bet anyway (a literal veterinarian by training, so long-shot horses are kind of his thing), and AZ says the difference is that its antibody blocks two IL-33 pathways instead of one, hitting both the inflammation and the mucus behind the disease. #winning.
Naturally, the Street went from six to midnight on the forecast. AstraZeneca now says $5 billion a year is a floor, not a ceiling, feeding its $80 billion revenue target for 2030 (Pfizer bid $118 billion for this entire company in 2014 and got told no… you hate to see it). Biopharma boss Ruud Dobber is already calling it potentially "one of the largest products in history" in respiratory. Which, we’ve heard that one before… (sup, Fauci).
To be fair though, there is one small fine print, and it comes courtesy of Dr. MeiLan Han, the University of Michigan lung boss who actually helped run these trials and would still like to see the receipts (read: more subgroup cuts) before anyone benches Dupixent, because nobody has run a head-to-head. Meaning the pulmonologists get to have another pissing match over sequencing well into 2027, and AZ's girthy respiratory pipeline (the same drug is already in trials for severe asthma and viral lung infections) says it can wait.
Regardless, the consensus had a literal zero in the model, and the same analysts who wrote it are about to spend a year pretending they believed the whole time. Cowards. Breathe easy, fellas. Until next time, friends…

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
